Envoy Medical reported a third-quarter net loss attributable to common stockholders of $5,240 thousand, or $0.50 per share, compared to a loss of $7,747 thousand, or $3.55 per share, in the prior-year period. Net revenue increased slightly to $66 thousand from $42 thousand. The company highlighted clinical progress on its investigational Acclaim cochlear implant, surpassing the six-month follow-up milestone for all 56 patients and submitting the second module of its Modular Premarket Approval application to the FDA. Additionally, litigation with Atlas Merchant Capital was dismissed without payment. Envoy Medical is a hearing health and neuroprosthetics company focused on fully implanted hearing solutions.
